Astellas Pharma (OTCMKTS:ALPMY) Issues Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) posted its quarterly earnings data on Wednesday. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.27, Zacks reports. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%.

Astellas Pharma Price Performance

OTCMKTS:ALPMY traded up $0.27 during trading hours on Wednesday, reaching $14.07. 40,207 shares of the company were exchanged, compared to its average volume of 169,892. The business has a 50 day moving average of $13.41 and a 200 day moving average of $14.63. Astellas Pharma has a 1-year low of $10.03 and a 1-year high of $17.35. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90. The company has a market capitalization of $25.46 billion, a P/E ratio of 13.10 and a beta of 0.08.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Astellas Pharma has a consensus rating of “Hold”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).